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Abstract
Prostate cancer (CaP) metastases selectively develop in bone as opposed to other sites through unknown mechanisms.
Interleukin-6 (IL-6) is considered to contribute to CaP progression and is produced at high levels in osteoblasts. We
hypothesized that osteoblast-derived IL-6 in the bone microenvironment contributes to the fertile soil for CaP growth.
Accordingly, human CaP cells, LNCaP, C4-2B and VCaP, were treated with conditioned medium (CM) collected from
human osteoblast-like HOBIT cells grown in androgen-depleted medium. We found that CM induced proliferation, prostate-
specific antigen (PSA) protein and mRNA expression in a dose-dependent manner in these cell lines as determined by ELISA
and real-time PCR, respectively. CM also activated the PSA promoter in these cells. Both HOBIT and primary osteoblast
(POB) cells produced high levels of IL-6 measured by bioassay. LNCaP, C4-2B and VCaP cells expressed IL-6, but at
much lower levels then the HOBIT and POB and they also expressed the IL-6 receptor mRNA, indicating they can respond
to IL-6. Anti-IL-6 antibody added to HOBIT or POB CM dose-dependently inhibited the CM-induced cell proliferation
and PSA expression in these CaP cell lines. HOBIT CM induced nuclear translocation of the AR and this was inhibited
by anti-IL-6 antibody. Additionally, the antiandrogen bicalutamide inhibited HOBIT CM-induced cell proliferation. These
results demonstrate that osteoblasts promote CaP growth through IL-6-mediated activation of the AR. Furthermore, these
data underscore the importance of cross-talk between tumor and the bone microenvironment in the development of CaP
bone metastases.
Abbreviations: AR – androgen receptor; BIC – bicalutamide; CaP – prostate cancer; CS-FBS – charcoal-stripped fetal
bovine serum; CM – conditioned media; DMEM – Dulbecco’s modified Eagles Medium; ELISA – enzyme-linked im-
munostaining assay; FBS – fetal bovine serum; FGF – fibroblast growth factor; GFP – green fluorescent protein; IGF –
insulin-like growth factor; IL-6 – interleukin-6; POB – huamn primary osteoblast; PSA – prostate-specific antigen; SDF –
stromal derived factor
Introduction
Prostate cancer (CaP) often progresses from an andro-
gen dependent cancer into an androgen independent cancer
that favors metastasis to bone compared to other sites in
greater than 90% of patients with prostate carcinoma [1–2].
However, mechanisms accounting for metastatic CaP cells’
skeletal preference are poorly understood. In accordance
with Paget’s ‘seed and soil’ hypothesis [3], it is possible that
factors in the bone microenvironment may provide a ‘fertile
soil’ allowing the ‘seed’ of CaP cells to grow. There are
many factors derived from the bone microenvironment that
may promote establishment and progression of CaP cells in
bone [reviewed in 4] and contribute to cross-talk between the
CaP cells and the bone microenvironment [reviewed in 5].
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Evidence in support of the possibility that bone-derived
factors contribute to the development of CaP metastases has
been derived from studies in which conditioned media from
bone cultures induced cancer cell growth of a variety of tu-
mor cell lines [6–8]. Several specific bone-derived factors
have been demonstrated to stimulate CaP cell growth in
vitro, including insulin-like growth factor-1 and 2 (IGF-1
and IGF-2) [9–10], fibroblast growth factor-8 (FGF-8) [8],
stromal-derived factor-1 (SDF-1) [11] and osteonectin [12–
13]. However, the mechanisms through which these factors
influence CaP cell proliferation have not been delineated.
One factor that is active on CaP cells and is produced
at high levels by osteoblasts is interleukin-6 (IL-6) [14].
IL-6 is a key mediator of inflammation and immunologic
reactions [15]. Elevated serum IL-6 levels are associated
with clinical morbidity of CaP patients [16–17]. IL-6 dir-
ectly affects benign and malignant CaP cell proliferation
depending on the cell type and differentiation stage [18–
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19]. IL-6 induces prostate-specific antigen (PSA) expression
through ligand-independent activation of the androgen re-
ceptor (AR) [20–21] that is mediated by multiple signaling
pathways including MAP kinases and Jak/Stats [22–23]. The
observation that osteoblasts produce high levels of IL-6 in
combination with the fact that IL-6 has many affects on CaP
cells suggests that bone-derived IL-6 may promote develop-
ment of CaP metastases. Accordingly, in this study we tested
the hypothesis that IL-6 contributes to osteoblast-induced
CaP proliferation and PSA expression in vitro.
Materials and methods
Cell culture and reagents
The human prostate cell lines, LNCaP and PC3 (Amer-
ican Type Tissue Collection, Manassas, Virginia), were
maintained in RPMI-1640 supplemented with 10% FBS,
100 U/l penicillin G, 100 µg/ml streptomycin, and 2 mM
L-glutamine. The human CaP cell line C4-2B (UroCor
Inc., Oklahoma City, Oklahoma), derived from LNCaP
cells after several passages through castrated nude mice
[24], were maintained in T medium, which consisted of
80% Dulbecco’s modified Eagles medium (DMEM, Life
Technologies Inc., Grand Island, New York), 20% F12K
(Irving Scientific, Santa Ana, California), 3 g/l NaHCO3,
100U/l penicillin G, 100 µg/ml streptomycin, 5 µg/ml in-
sulin, 13.6 pg/ml triiodothyronine, 5 µg/ml apo-transferrin,
0.25 µg/ml biotin, 25 µg/ml adenine, and were supplemen-
ted with 10% FBS. The human CaP cell line VCaP, derived
from a vertebral metastatic lesion [25], was maintained
in DMEM supplemented with 10% FBS, 100 U/l penicil-
lin G, 100 µg/ml streptomycin, and 2 mM L-glutamine.
Human osteoblast-like HOBIT cells (kindly provided by
Dr. L Riggs, Mayo Foundation, Rochester, Minnesota) were
grown in DMEM supplemented with 10% (v/v) fetal calf
serum, 2 mM L-glutamine and penicillin/streptomycin. Hu-
man primary osteoblasts (POB) were obtained from femoral
head trabecular explants derived from patients undergoing
hip replacement surgery. Tissue procurement was approved
by the University of Michigan Institutional Review Board.
Briefly, the trabecular bone was scraped into bone chips and
further processed with a bone grinder. Bone chips were cul-
tured in MEM supplemented with 20% FBS. The presence
of osteoblast cells was confirmed by RT-PCR for alkaline
phosphatase and osteocalcin mRNA expression and histo-
chemical staining for alkaline phosphatase using the Sigma
Diagnostics Phosphatase kit (Sigma Diagnostic, Inc, St.
Louis, Missouri). Cultures consisted of greater then 90%
osteoblasts. All cells were grown at 37 ◦C in a humidified
atmosphere containing 5% CO2. Anti-human IL-6 antibody
(CLB, Amsterdam, The Netherlands) is a mouse mono-
clonal (subtype IgG1) specific for human IL-6. Mouse IgG1
(Sigma, St. Louis, Missouri) was used as an isotype control
antibody. Recombinant human IL-6 was purchased from R
& D systems (Minneapolis, Minnesota). The antiandrogen,
bicalutamide (BIC) (Zeneca Pharmaceuticals, Macclesfield,
UK) was provided by Dr. K. Olsen (University of Michigan,
Ann Arbor, Michigan).
Preparation of conditioned media (CM) from HOBIT and
POB
HOBIT and POB cells were grown in 10-cm tissue cul-
ture dishes with their respective maintenance medium until
they reach 80% confluent, then the medium was replaced
with 10 ml of DMEM with 0.5% charcoal-stripped FBS and
continued culturing for 48 h. Supernatants were collected
as CM. To normalize for differences in cell density due to
proliferation during the culture period, cells from each plate
were collected, and total DNA content/plate was determined
(spectrophotometric absorbance at 260 nm). CM was then
normalized for DNA content between samples by adding
DMEM.
Cell proliferation assay
Cell proliferation was measured using the CellTiter 96
AQ nonradioactive cell proliferation assay (Promega Corp.
Madision, Wisconsin). Briefly, LNCaP, C4-2B, and VCaP
cells were plated in their maintenance medium in wells of a
96-well plate at 5,000/well in triplicates. After 12 h of cul-
ture, the medium was changed to DMEM plus 0.5% CS-FBS
and a different concentration (0–50%) of CM and/or indic-
ated concentration of anti-IL-6 antibody or isotype control
(500 ng/ml), recombinant human IL-6 (10 ng/ml), or in-
dicated concentration of anti-androgen, bicalutamide (BIC)
was added. The cells were incubated for 48 h, and then
20 µl/well of combined MTS/PMS solution was added.
After 1 h at 37 ◦C in a humidified 5% CO2 atmosphere, the
absorbance at 490 nm was recorded by using an ELISA plate
reader.
Transfection and prostate specific antigen (PSA) promoter
activity measurement
A 5.8 kb fragment of the human PSA promoter was sub-
cloned into pGL-2 (Promega Corp, Madison, Wisconsin)
to create pGLPSAp5.8. LNCaP, C4-2B, and VCaP cells
were grown to 80% confluence in T75 flasks, trypsinized,
washed in phosphate buffered saline (PBS), and replated at
1 × 105 cells/well in 12-well culture plate in maintaining
media. Twelve hours after plating, cells were co-transfected
with pGLPSAp5.8 (1 µg) and pRL-SV40 vector (Promega
Corp; 50 ng) using Transfast transfection assay (Promega
Corp). Twenty-four hours after transfection, the medium
was changed to DMEM with 0.5% CS-FBS, and cells were
treated with various concentrations (v/v) of conditioned me-
dium (CM) collected from HOBIT or POB for 24 h. The
cells were then lysed with luciferase lysis buffer (Promega
Corp) and the luciferase activity was quantified using a lu-
minometer (Turner Designs, Sunnyvale, California) using
the protocol from Dual-Luciferase Reporter assay system
(Promega Corp).
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Measurement of PSA protein levels
LNCaP, C4-2B, and VCaP cells were plated in 12-well-
plates in their maintenance medium at 3 × 105/well in
triplicates. After 12 h of culture, the medium was changed
to DMEM plus 0.5% CS-FBS and a different concentration
(0–50%) of CM and/or indicated concentration of anti-IL-
6 antibody or isotype control (500 ng/ml), or recombinant
human IL-6 (10 ng/ml) were added. PSA protein in the cul-
ture supernatant was measured following the manufacture’s
protocol by using the ACCUCYTE human PSA assay kit
(Cytiimmune Sciences Inc. College Park, Massachusetts)
and normalized to total cellular DNA that extracted from the
cells using DNeasy kit (Qiagen, Valencia, California). The
sensitivity of the assay is 0.488 ng/ml.
Quantification of PSA mRNA expression by real-time PCR
LNCaP, C4-2B, and VCaP cells were plated in their
maintenance medium into 12-well-plates at 3 × 105/well
in triplicates. After 12 h of culture, the medium was
changed to DMEM plus 0.5% CS-FBS and a vari-
ous concentrations (0–50%) of CM were added. The
cells were grown for 48 hours and total RNA was
isolated from the cell lysates using Trizol (Invitro-
gen, Carlsbad, California). Message RNA expression
was determined using real-time PCR on the LightCycler
(Roche Diagnostics) for PSA and normalization to β2-
microglobulin. The primer sequences used were: PSA sense,
5′-GGCAGGTGCTTGTAGCCTCTC-3′; PSA antisense, 5′-
CACCCGAGCAGGTGCTTTTGC-3′; β2-microglobulin,
sense, 5′-ATGCCTGCCGTGTGAACCATGT-3′; and β2-
microglobulin antisense 5′-AGAGCTACCTGTGGAGCAA
CCT-3′.
Measurement of IL-6 by ELISA
CM collected from HOBIT and POB were assayed for IL-6
using a human ELISA kit (R&D Systems) as recommended
by the manufacturer. The minimum dose of IL-6 detectable
is 0.7 pg/ml. For measuring IL-6 production by CaP cells,
LNCaP, C4-2B, VCaP, and PC3 cells were plated in their
maintenance medium into10-cm tissue culture dishes and
incubated until they reached 80% confluency, then the media
was replaced with 10 ml of DMEM with 0.5% charcoal-
stripped FBS. The cell supernatants were collected after an
additional 48 h of culture. To normalize for differences in
cell density due to proliferation during the culture period,
cells from each plate were collected, and total DNA con-
tent/plate was determined (spectrophotometric absorbance at
260 nm). CM was then normalized for DNA content between
samples by adding DMEM.
Measurement of bioactive IL-6 using B9 Bioassay
Bioactive IL-6 was measured using the B9 cell bioassay as
previously reported with minor modifications [26]. Briefly,
B9 cells were maintained in RPMI 1640 supplemented with
10% FBS and 5ng/ml recombinant human IL-6 (Promega
Corp). Cells at 2 × 103/well in triplicates were plated in
100ul of RPMI 1640 with 10% FBS in 96-well plate. Various
concentration of CM (v/v) from HOBIT and/or anti-IL-6 an-
tibody or isotype control (both at 500 ng/ml) were added into
the wells in volume of 100 ul. Recombinant human IL-6 was
used as a positive control. The cells were cultured for 48 h
at 37 ◦C in 5% CO2 incubator. Then 20 µl/well of combined
MTS/PMS solution (Promega Corp) was added into each
well. After incubation of 1 h at 37 ◦C in a humidified 5%
CO2 atmosphere, the absorbance at 490 nm was recorded by
using an ELISA plate reader.
Measurement of IL-6 receptor (IL-6R) mRNA expression by
RT-PCR
LNCaP, C4-2B, VCaP, and PC3 cells were plated in
their respective maintenance medium into 60 mm plates
at 2 × 106 cells/plate. The cells were allowed to grow
for 12 hours, total RNA was then isolated using Tri-
zol (Invitrogen). IL-6R mRNA expression was determ-
ined using reverse transcriptase-polymerase chain reac-
tion (RT-PCR). The primer sequences used were: sense,
5′-CATTGCCATTGTTCTGAGGTTC-3′; antisense, 5′-
AGTAGTCTGTATTGCTGATGTC-3′, resulting in a PCR
product of 251 bp. The PC3 cell line was used as a positive
control for IL-6R expression. RT-PCR was performed with
1 µg of total RNA using the Access RT-PCR system (Pro-
mega Corp), as directed by the manufacturer, in a thermal
cycler (GeneAmp PCR system 9700; Perkin-Elmer Applied
Biosystems, Foster City, California) under the following
conditions: first-strand cDNA was synthesized at 48 ◦C for
45 min; then denatured at 94 ◦C for 2 min for the first cycle
and at 15 sec for additional 40 cycles; annealing was per-
formed at 55 ◦C for 30 sec; and extension at 72 ◦C for 60 sec.
Final extension was at 72 ◦C for 5 min. The PCR products
were subjected to electrophoresis on a 1.5% agarose gel,
stained with ethidium bromide.
Detection of AR nuclear translocation
Fluorescent detection of nuclear AR translocation was per-
formed as a modification of a procedure we have previously
described [20]. Briefly, an expression plasmid consisting of
AR fused to green fluorescent protein (GFP) (a gift from
Dr M. Lu, Harvard University, Boston, Massachusetts) was
stably-transfected into C4-2B cells. Sterile glass coverslips
were placed in wells of 12-well plates. C4-2B cells were then
added in their maintenance medium at 3 × 105 cells/well.
After 12 hours of culture, the medium was changed to
DMEM plus 0.5% CS-FBS and 25% HOBIT CM and/or
increasing dose of anti-IL-6 antibody or isotype control
(500 ng/ml), or recombinant human IL-6 (10 ng/ml). Fol-
lowing 48 hrs of culture, the coverslips were rinsed once in
PBS and fixed with 4% paraformaldehyde in PBS pH 7.4 for
10 min. Paraformaldehyde was then neutralized with a 5 min
exposure to 50 mM NH4Cl in PBS. The coverslips were
then washed twice in PBS. Coverslips were incubated for
15 min with 1% BSA, NFDM, 0.3% Triton X-100 in PBS,
then for 1 h in rabbit anti-AR (N-20) (Santa Cruz Biotech-
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Figure 1. HOBIT CM induces LNCaP, C4-2B, and VCaP cell proliferation.
LNCaP, C4-2B and VCaP cells were seeded in triplicates at 5000 cells/well
in their maintaining media in 96-well plate. Twelve hours later, the media
was changed to DMEM supplemented with 0.5% charcoal-striped FBS.
Then LNCaP, C4-2B, and VCaP cells were treated various concentrations
(v/v) of HOBIT CM as indicated. The cells were allowed to grow 48 hours,
then the cell proliferation assay was performed using MTS assay. Data are
presented as Mean ± SD of OD value. ∗P < 0.01 vs 0% CM-treated cells;
∗∗P < 0.001 vs 0% CM-treated cells.
nology, Santa Cruz, California) diluted 1:100 in 1% BSA,
5% NFDM, and 0.1% Tween 20 in PBS. The slips were then
extensively washed in PBS-Tween-20 and incubated for 1 h
with goat anti-rabbit IgG conjugated with FITC (Santa Cruz
Biotechnology) diluted 1:500 in 1% BSA, 5% NFDM, and
0.1% Tween 20 in PBS. The images were captured using a
fluorescent microscope.
Data analysis
One way ANOVA was used for all studies. Fisher’s least-
significant difference was used for post hoc analysis. P -
values less than or equal to 0.05 were considered to be
statistically significant.
Results
CM from HOBIT induces CaP cell proliferation
To test if the factors from human osteoblast-like HOBIT
cells induce CaP cell growth, LNCaP, C4-2B, and VCaP
cells were incubated with increasing dose of androgen-
depleted CM collected from HOBIT cells. HOBIT CM
induced proliferation in a dose dependent manner in these
cell lines (Figure 1). When CaP cells were treated with 25%
CM, the cell proliferation was induced over 2-fold compared
to the no CM added controls. These results indicate that
HOBIT cells produce soluble factors that induce CaP cell
proliferation. This result is consistent with the previous re-
port that LNCaP cell proliferation is increased in response to
CM collected from primary human osteoblast culture [27].
Figure 2. HOBIT CM induces PSA protein and mRNA expression in
LNCaP, C4-2B, and VCaP cells. (A) LNCaP, C4-2B, and VCaP cells in
their maintaining media were added to the 12-well-plate in triplicates. After
12 hours of culture, the media was changed to DMEM plus 0.5% CS-FBS
and a different concentration (0–50%) of CM were added. PSA protein was
measured using the ACCUCYTE human PSA assay kit and normalized to
total cellular DNA that extracted from the cells using DNeasy kit. Data are
presented as Mean ± SD from triplicates. ∗P < 0.01 vs 0% CM-treated
cells. ∗∗P < 0.001 vs 0% CM-treated cells; †P < 0.01 vs LNCaP cells.
(B) Total RNA was isolated from the cell lysates. Message RNA expression
was tested by real-time PCR for PSA and normalized to β2-microglobulin.
Data are presented as Mean ± SD from triplicates. ∗P < 0.01 vs 0%
CM-treated cells; ∗∗P < 0.001 vs 0% CM-treated cells; †P < 0.01 vs
LNCaP cells.
CM from HOBIT induces PSA protein and mRNA
expression in CaP cells
To investigate if CM from HOBIT cells induce PSA pro-
tein and mRNA expression, LNCaP, C4-2B and VCaP cells
were treated with increasing dose of androgen-depleted CM
collected from HOBIT cells. HOBIT CM induced PSA pro-
tein and mRNA expression in LNCaP, C4-2B, and VCaP
cells in a dose dependent manner (Figures 2A and B). When
LNCaP, C4-2B, and VCaP cells were treated with 25% CM,
the PSA protein levels were induced over 3-fold compared
to the cells in which vehicle control CM was added control.
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Figure 3. HOBIT CM induces PSA promoter activity in LNCaP, C4-2B,
and VCaP cells. LNCaP, C4-2B and VCaP cells were transiently transfected
with pGLPSAp5.8 and PRL-SV40 vector as internal control as described in
Materials and methods. Cells were treated with various concentration of
HOBIT CM or DHT (as positive control), cell extracts were assayed for
luciferase activity. Data are represented as Mean ± SD of relative luci-
ferase activity from triplicate samples. ∗P < 0.01 vs 0% CM-treated cells;
∗∗P < 0.001 vs 0% CM-treated cells.
The magnitude of induction of protein levels was consistent
with the induction of PSA mRNA expression. These results
suggest that HOBIT cells produce a soluble factor that has a
pro-androgenic effect.
CM from HOBIT induces PSA promoter activity in CaP
cells
To investigate whether the induction of PSA mRNA by
HOBIT CM is due to induction of PSA gene transcription,
we used a reporter plasmid containing the PSA promoter
driving luciferase to transfect LNCaP, C4-2B, and VCaP
cells. CM from HOBIT cells dose-dependently induced
this promoter activity in these cells (Figure 3). CM at
25% induced the PSA promoter over 5-fold in these cell
lines. This result indicates that HOBIT cell CM-induced
PSA mRNA expression occurs through activation of PSA
promoter transcription.
CM from HOBIT and primary osteoblasts (POB) contains
bioactive IL-6
IL-6 has been considered to be an important factor in CaP
progression. It has been shown that osteoblasts produce IL-6
[28] and IL-6 is able to activate the AR [20, 29]. Therefore, it
is possible that IL-6 may contribute to HOBIT CM-induced
PSA expression through activation of the AR. To test this,
we first measured IL-6 levels in the HOBIT CM. HOBIT
produced a high amount of immunoreactive IL-6 as determ-
ined by ELISA (Figure 4A). To test whether the secreted
IL-6 was bioactive, the HOBIT CM was subjected to B9
bioassay for IL-6. HOBIT CM induced B9 cell prolifer-
ation in a dose-dependent fashion and anti-IL-6 antibody
blocked this activity (Figure 4B). This result demonstrates
that HOBIT CM contains bioactive IL-6. To determine the
relevance of HOBIT IL-6 production to osteoblasts, we sub-
jected POB CM to IL-6 ELISA. POB CM contained levels
of IL-6 similar to those of HOBIT cells (Figure 4A).
Figure 4. HOBIT CM and POB CM contain bioactive IL-6; LNCaP,
C4-2B, and VCaP cells produce low levels of IL-6 and express IL-6R.
(A) HOBIT CM and POB CM, and cell culture supernatant collected from
LNCaP, C4-2B, VCaP, and PC3 were measured for IL-6 using a human
ELISA. Data are represented as Mean ± SD from triplicate samples. (B) B9
bioassay was performed for measuring bioactive IL-6 in the HOBIT CM.
Data are represented as Mean ± SD of the OD value from triplicate samples.
∗P < 0.01 vs 0% CM-treated cells; ∗∗P < 0.001 vs 0% CM-treated
cells; †P < 0.001 vs 25% CM-treated cells; ¶P < .01 vs 0% CM-treated
cells. (C) Total RNA was isolated from LNCaP, C4-2B, VCaP, and PC3 cell
lysates. IL-6R mRNA expression was determined by RT-PCR. The PC3
cell line was used as a positive control for IL-6R expression. The PCR
products were subjected to electrophoresis on a 1.5% agarose gel, stained
with ethidium bromide.
CaP cells produce low levels of IL-6 and express IL-6
receptor
IL-6 has been shown to be produced at different levels by
different CaP cell lines, and it functions through binding to
its receptor on the CaP cells. It differentially regulates an-
drogen receptor transactivation via PI3K-Akt, JNK/STAT3,
and MAPK signal pathways [22]. To test if various CaP
cell lines produce IL-6 we measured IL-6 expression in the
supernatants. IL-6 levels were undetectable in LNCaP CM,
whereas IL-6 levels were low compared to HOBIT and POB
CM in the C4-2B and VCaP CM. PC3 CM had high levels of
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Figure 5. Anti-IL-6 antibody inhibits HOBIT CM- or POB CM-induced cell proliferation and PSA protein expression in LNCaP, C4-2B, and VCaP cells.
(A) LNCaP, C4-2B and VCaP cells were seeded in triplicates at 5000 cells/well in their maintaining media in 96-well plate. Twelve hours later, the
media was changed to DMEM supplemented with 0.5% charcoal-striped FBS. Then LNCaP, C4-2B, and VCaP cells were treated 25% HOBIT CM and/or
indicated concentrations of anti-IL-6 antibody or isotype control (500 ng/ml), or recombinant human IL-6 (10 ng/ml). The cells were allowed to grow
48 hours, then the cell proliferation assay was performed using MTS assay. Data are presented as Mean ± SD of OD value. ∗P < 0.001 vs non-treated
cells; †P < 0.001 vs 25%CM-treated cells; ¶P < 0.01 vs non-treated cells. (B) LNCaP, C4-2B and VCaP cells in their maintaining media were added
to the 12-well-plate at 3 × 105/well in triplicates. After 12 hours of culture, the media was changed to DMEM plus 0.5% CS-FBS and 25% HOBIT CM
and/or indicated concentrations of anti-IL-6 antibody or isotype control (500 ng/ml), or recombinant human IL-6 (10 ng/ml). PSA protein in the culture
supernatant was measured using the ACCUCYTE human PSA assay kit and normalized to total cellular DNA. Data are presented as Mean ± SD of OD
value. ∗P < 0.001 vs Non-treated cells; †P < 0.001 vs 25%CM-treated cells; ¶P < 0.01 vs non-treated cells. (C) LNCaP, C4-2B, and VCaP cells
in their maintaining media were added to the 12-well-plate at 3 × 105/well in triplicates. After 12 hours of culture, the media was changed to DMEM
plus 0.5% CS-FBS and 25% POB CM and/or indicated concentrations of anti-IL-6 antibody or isotype control (500 ng/ml), or recombinant human IL-6
(10 ng/ml). PSA protein in the culture supernatant was measured using the ACCUCYTE human PSA assay kit and normalized to total cellular DNA. Data
are presented as Mean ± SD of OD value. ∗P < 0.001 vs Non-treated cells; †P < 0.001 vs 25%CM-treated cells; ¶P < 0.01 vs non-treated cells.
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IL-6 (Figure 4A). To determine if CaP cells can respond to
IL-6, we determined if the IL-6R was present. We found that
LNCaP, C4-2B, VCaP, and PC-3 cells express IL-6R mRNA
as identified by RT-PCR (Figure 4C). Taken together, these
results suggest that osteoblasts produce higher levels of IL-
6 than CaP cells and that the CaP cells can respond to IL-6
through the IL-6R.
Anti-IL-6 antibody inhibits HOBIT-CM and
POB-CM-induced CaP cells proliferation and PSA
expression
To test whether IL-6 induces LNCaP, C4-2B and VCaP cell
proliferation and PSA production in vitro, the cells were
treated with recombinant IL-6. We found that IL-6 induced
the proliferation of LNCaP, C4-2B, and VCaP cells (Fig-
ure 5A) and PSA production from these cells (Figure 5B). To
test if HOBIT CM induced CaP proliferation and PSA pro-
duction through IL-6, the CaP cells were grown in HOBIT
CM supplemented with increasing doses of anti-IL-6 anti-
body. HOBIT CM induced LNCaP, C4-2B, and VCaP cell
proliferation (Figure 5A) and PSA production (Figure 5B).
Anti-IL-6 antibody inhibited the HOBIT CM-induced CaP
cell proliferation (Figure 5A) and PSA production (Fig-
ure 5B) in a dose-dependent fashion. Additionally, anti-IL-6
alone reduced basal levels of LNCaP, C4-2B, and VCaP
proliferation and PSA production (Figures 5A and B). To
determine if these results extend to POB, we incubated the
CaP cells with POB CM in the presence and absence of anti-
IL-6 antibody. Similar to the HOBIT CM, POB CM induced
LNCaP, C4-2B, and VCaP proliferation and PSA production
and anti-IL-6 antibody blocked these activities (Figure 5C).
Anti-IL-6 antibody inhibits HOBIT-CM-induced AR nuclear
translocation in C4-2B cells
We have previously demonstrated that recombinant IL-6
activates AR nuclear translocation in CaP cells [20]. To
investigate whether HOBIT CM induces AR nuclear trans-
location through IL-6, various dose of neutralizing anti-IL-6
antibody was added to HOBIT CM (25%)-treated C4-2B
cells that were stably transfected with an AR-GFP fusion
vector. HOBIT CM induced AR translocation and neutraliz-
ing anti-IL-6 antibody dose-dependently inhibited HOBIT-
CM-induced AR nuclear translocation in C4-2B cells (Fig-
ure 6A). These results indicate that osteoblast-derived IL-6
induces AR translocation in C4-2B cells.
Antiandrogen inhibits HOBIT-CM-induced CaP cell
proliferation
Antiandrogens, such as BIC, were designed to treat ad-
vanced CaP through interfering with AR-mediated cell sur-
vival and through initiating cell death [30]. To test whether
HOBIT CM-induced CaP cell proliferation through AR, we
incubated LNCaP, C4-2B, and VCaP cells in HOBIT CM
with the addition of BIC. We found that BIC inhibited
HOBIT-CM-induced cell proliferation in a dose-dependent
fashion in these cells (Figure 6B). These results demonstrate
that HOBIT CM induces CaP proliferation through the AR.
Figure 6. Osteoblast-derived IL-6 induces CaP cell proliferation through
the androgen receptor (AR). (A) C4-2B cells in their maintaining media
were added to the glass coverslips in 12-well-plate at 3×105/well. After 12
hours of culture, the media was changed to DMEM plus 0.5% CS-FBS and
25anti-IL-6 antibody or isotype control (500 ng/ml), or recombinant human
IL-6 (10 ng/ml). Immunofluorescent imaging was captured after 48 hrs
cell culture using a fluorescent microscope. Panel A: non-treated cells;
panel B: 25% CM; panel C: 25% CM plus anti-IL-6 antibody (5 ng/ml);
panel D. 25% CM plus anti-IL-6 antibody (50 ng/ml); panel E. 25% CM
plus anti-IL-6 antibody (500 ng/ml); panel F: 25(500 ng/ml). (B) LNCaP,
C4-2B and VCaP cells were seeded in triplicates at 5000 cells/well in their
maintaining media in 96-well plate. Twelve hours later, the media was
changed to DMEM supplemented with 0.5% charcoal-striped FBS. Then
LNCaP, C4-2B, and VCaP cells were treated various concentrations of BIC.
The cells were allowed to grow 48 hours, then the cell proliferation assay
was performed using MTS assay. Data are presented as Mean ± SD of OD
value from triplicates. ∗P < 0.01 vs non-treated cells; ∗∗P < 0.001 vs
25% CM-treated cells.
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Discussion
CaP metastases selectively develop in bone [31–32]. It is
unclear if the bone selectivity is due to the cancer cells’
ability to home to bone or if the bone microenvironment is
conducive to CaP cell growth. Most likely it is a combination
of these activities. In the current study, we demonstrated
that IL-6 is an osteoblast-derived factor that induces CaP
cell proliferation through activation of the AR. This find-
ing supports Paget’s seed and soil hypothesis [3] through
demonstrating that a factor produced in the bone microenvir-
onment contributes to growth of cancer cells that selectively
metastasize to bone.
In addition to its role as a key mediator of inflammation
[15], IL-6 has pleiotropic effects in CaP cell biology [re-
viewed in 23]. It has been shown that IL-6 and its receptor
are expressed on CaP cell lines [18–19] as we identified
in two additional CaP cell lines, C4-2B and VCaP, in the
current study. Furthermore, IL-6 serum levels are elevated
in patients with hormone refractory CaP compared to those
with localized disease [16–17]. However, the source of
serum IL-6 is unknown. Although the CaP cells themselves
produced IL-6, we found that the levels produced by os-
teoblasts were significantly higher, thus the major source of
serum IL-6 is more likely from bone as opposed to the can-
cer cells. Furthermore, because the osteoblast-derived IL-6
is produced at a much higher level than that from the cancer
cells themselves, it is possible that the osteoblast-derived IL-
6 acts in paracrine manner in the CaP cells above and beyond
the autocrine IL-6 activity. However, we cannot rule out that
in the bone microenvironment CaP cells gain the ability to
produce increased amounts of IL-6. It has been previously
documented that CaP cells gain an osteoblast-like phenotype
[33–34] which is consistent with the possibility that they
also gain the ability to produce more IL-6. Measurement
of serum human IL-6 in the mice implanted with tumor in
the current study did not show any changes during tumor
growth (data not shown). However, this may be due to the
small volume of tumor compared to the whole animal and
that IL-6 may have been diluted. At this point it is not clear if
the bone microenvironment influences the ability of prostate
cancer cells to produce IL-6.
The effect of IL-6 on CaP cell proliferation has generated
contradictory results in vitro. For example, several stud-
ies demonstrated that IL-6 inhibits LNCaP cell proliferation
[19, 21, 35] and induces the cells towards neuroendocrine
differentiation [36–40]; whereas, other studies revealed that
IL-6 induced cell growth [41]. The ability of IL-6 to pro-
mote differentiation of cancer cells may account for the
decreased proliferation in some instances. In contrast, IL-
6 induced androgen-independent CaP cell growth in several
studies [18, 42], although, on one study, IL-6 had no ef-
fect on androgen-independent CaP cell proliferation [19];
however, in that same study, anti-IL-6 inhibited the prolif-
eration of the androgen-independent lines suggesting that
there was an autocrine proliferative effect that was max-
imally stimulated. Furthermore, IL-6 has been shown to
have an anti-apoptotic effect on both basal and chemother-
apy induced apoptosis of CaP cells [43–45]. In support of
the in vitro data, the administration of anti-IL-6 antibody
inhibited PC-3 CaP tumor growth in vivo [46]. The anti-
IL-6 antibody administration was associated with increased
apoptosis of tumor cells. In the current study, the obser-
vation that anti-IL-6 antibody blocked HOBIT-induced and
POB-induced CaP proliferation and PSA production sug-
gests that HOBIT and POB cells promote CaP proliferation
and PSA production through IL-6. Additionally, the ob-
servation that anti-IL-6 antibody inhibited basal CaP cell
proliferation and PSA expression, combined with our identi-
fication that these cells express both IL-6 and IL-6 receptor,
suggests that these cells respond to IL-6 in an autocrine fash-
ion. Taken together, our results indicate that the CaP cells
respond to IL-6 in both an autocrine and paracrine fashion,
which suggests that osteoblast-derived production of IL-6
in the bone microenvironment favors CaP growth or sur-
vival. These data demonstrate that IL-6 has complex effects
on CaP and suggest IL-6 contributes to the progression of
both androgen-dependent and androgen-independent cancer
in vitro.
The mechanisms through which IL-6 modulates CaP cell
activity are not clear. IL-6 has been reported to activate
multiple signaling pathways in CaP cells including the PI-
3 kinase [45], Jak/Stat [47], and MAP kinase [48] pathways.
Initiation of these pathways results in activation of the AR
in some instances. IL-6 has been demonstrated to activate
the AR in the absence of androgen resulting in PSA pro-
duction [20–22]. Consistent with these previous reports, we
identified, in the current study, that HOBIT CM-induced
AR nuclear translocation through IL-6. Proof of the func-
tional importance of the AR induction was provided by the
demonstration that the anti-androgen BIC, which completely
blocks AR function [49], blocked HOBIT CM-induced CaP
cell proliferation. This is consistent with previous reports in
which BIC has been shown to block IL-6-induced AR nuc-
lear translocation [20] and PSA production [20–21]. These
data suggest that osteoblasts can provide the signal neces-
sary to activate the AR and promoter CaP progression in
bone.
The bone microenvironment is rich in many growth
factors that have the potential to promote cancer growth in
bone [reviewed in 5]. It has been postulated that tumor-
induced osteolysis results in release of growth factors, such
as transforming growth factor-β, that are sequestered in the
bone matrix [reviewed in 50]. The current study demon-
strates that, in addition to these matrix-derived factors,
cells in the bone microenvironment can produce factors that
promote cancer cell growth in bone.
In conclusion, the current study demonstrated that IL-6
is a key mediator of osteoblast-induced CaP cell prolifer-
ation and PSA expression through activation of the AR.
This finding supports the idea that cross-talk between the
bone microenvironment and CaP cells promotes tumor es-
tablishment and progression in bone. Identifying the factors
that mediate cross-talk between the bone microenvironment
and tumor may lead to identification of therapeutic targets.
Accordingly, this study suggests that further exploration of
Osteoblasts induce prostate cancer growth through IL-6 407
IL-6 as a putative target to diminish the development and
progression of bone metastases is warranted.
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